Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  alemtuzumab
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-7 of 7 for your search:
Start Over
Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: 2012-0501, NCI-2013-01666, NCT01875237
CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Under 22
Sponsor: Other
Protocol IDs: AAAK8060, NCT02061800
Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 10 to 80
Sponsor: NCI, NHLBI
Protocol IDs: 140077, 14-H-0077, NCT02105766
Reduced Intensity Conditioning in Patients Aged =35 With Non-Malignant Disorders Undergoing UCBT, BMT, or PBSCT
Phase: Phase II
Type: Treatment
Status: Active
Age: 2 months to 30 years
Sponsor: Other
Protocol IDs: RIC for HSCT in NMD, PRO13100018, NCT01962415
Phase II Clinical Trial of Alemtuzumab to Treat B-cell Chronic Lymphocytic Leukemia
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: CMAB004, NCT01982175
Reduced Intensity Conditioning for Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (BMT CTN 1204)
Phase: Phase II
Type: Treatment
Status: Active
Age: 4 months to 45 years
Sponsor: NCI, Other
Protocol IDs: BMTCTN1204, 2U10HL069294-11, NCT01998633
Lymphoma Bridge Transplant Study
Phase: No phase specified
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: 1208012875, NCT02059239
Start Over